![]() Inflammation and/or other disease processes in the skin increase percutaneous absorption. Topical corticosteroids can be absorbed from normal intact skin. Registrant - Novel Laboratories, Inc.Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA)Ĩ0 g in 1 TUBE Type 0: Not a Combination Productġ5 g in 1 TUBE Type 0: Not a Combination Product If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted. ![]() Reapplication is essential at each dressing change. When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). The frequency of changing dressings is best determined on an individual basis. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges. Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. This preparation is not for ophthalmic use.Īpply a thin film of the 0.1% Triamcinolone Acetonide Ointment USP, as appropriate, to the affected area two to three times daily. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary.Ĭhildren may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use). Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique. Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. ![]() Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.Ĭonditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. ![]() Some of the topical corticosteroids and their metabolites are also excreted into the bile. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Corticosteroids are bound to plasma proteins in varying degrees. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |